`
`https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020613
`
`
`
`
`
`
`
`Approval Date(s) and History, Letters, Labels, Reviews for NDA 020613
`
`Labels for NDA 020613
`
`No
`
`Yes
`
`None
`
`Discontinued
`
`SOLUTION/DROPS;OPHTHALMIC
`
`Showing 1 to 1 of 1 entries
`
`for safety or effectiveness reasons**
`product was not discontinued or withdrawn
`0.2% **Federal Register determination that
`
`TARTRATE
`BRIMONIDINE
`
`ALPHAGAN
`
`RS
`
`RLD
`
`Code
`TE
`
`Status
`Marketing
`
`Dosage Form/Route
`
`Strength
`
`Ingredients
`Active
`
`Name
`Drug
`
`
`Excel
`
`CSV
`
`Products on NDA 020613
`
`EVENT=OVERVIEW.PROCESS%26VARAPPLNO=020613)
`EMAIL (MAILTO:?SUBJECT=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&BODY=HTTP://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?
`
`Company: ALLERGAN
`New Drug Application (NDA): 020613
`
`Home (index.cfm) | Previous Page
`
`Drugs@FDA: FDA-Approved Drugs
`
`Drug Databases (https://www.fda.gov/Drugs/InformationOnDrugs/default.htm)
`
`Drugs@FDA: FDA-Approved Drugs
`
`12/8/22, 6:30 PM
`
`Slayback Exhibit 1060, Page 1 of 2
`Slayback v. Eye Therapies - IPR2022-00142
`
`
`
`2/2
`
`https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020613
`
`Drugs@FDA: FDA-Approved Drugs
`
`12/8/22, 6:30 PM
`
`Slayback Exhibit 1060, Page 2 of 2
`Slayback v. Eye Therapies - IPR2022-00142
`
`